WARREN, NJ, December 17, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (Tevogen or Tevogen Bio Holdings Inc.) (Nasdaq: TVGN), a clinical-stage immunotherapy biotechnology creating off-the-shelf, genetically engineered T cells modified. therapeutics to deal with infectious illnesses and cancers, as we speak introduced that it’s going to host an thrilling panel dialogue, Pioneering Well being Economics: Balancing Entry and Outcomes, on the forty third Annual JP Morgan Healthcare Convention.
This panel will convey collectively international thought leaders to look at the crucial interdependencies of the healthcare ecosystem, a dynamic interaction between affected person accessibility, medical innovation, reimbursement mechanism and healthcare coverage typically neglected when We solely think about one silo. The dialogue will deal with:
- The challenges and alternatives introduced by U.S. management in healthcare innovation, notably in balancing rising prices and worth creation.
- The impression of value containment measures, together with the Inflation Discount Act, on drug improvement and affected person entry.
- The implications of the brand new administration’s method to U.S. healthcare for international markets and the medical innovation business’s enterprise mannequin.
Panelists embody Senior Accomplice at Simon-Kucher; former Appearing Undersecretary of Well being for the Division of Veterans Affairs and former Commissioner of the New Jersey Division of Well being; Director, Rubix Well being, and Principal Investigator, Tufts Middle for Analysis of Worth and Danger in Well being and Enterprise Mentor, Johns Hopkins Tech Ventures, former CMS Chief Scientific Officer and Director of the Workplace of Scientific Requirements; Managing Director of Danger Advisory Companies, Veritas; CEO of Tevogen Bio; CIO and Head of AI at Tevogen Bio.
Occasion Particulars
Date:
Monday January 13, 2025
Location:
Marines’ Memorial Membership & Resort 609 Sutter St, San Francisco, CA 94102, United States
Time (PST):
3:15 p.m. “4:00 p.m.” Pioneering well being economics: balancing entry and outcomes
4:00 p.m. “6:00 p.m.” Reception and cocktails
For inquiries concerning extra occasion particulars, please contact communications@tevogen.com.
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy firm harnessing certainly one of nature’s strongest immunological weapons, CD8+ cytotoxic T cells, to develop off-the-shelf, genetically unmodified precision T cell therapies for remedy of infectious illnesses, cancers and neurological problems. geared toward addressing the unmet wants of huge affected person populations. Tevogen Management believes that sustainability and industrial success in as we speak’s healthcare period depends on making certain affected person accessibility by superior science and modern enterprise fashions. Tevogen has reported optimistic security knowledge from its proof-of-concept medical trial, and its core mental property property are absolutely owned by the corporate and usually are not topic to any third-party licensing agreements. These property embody three issued, 9 pending U.S. patents and twelve pending non-U.S. patents, two of which relate to synthetic intelligence.
Tevogen is led by a crew of extremely skilled business leaders and distinguished scientists with expertise in drug improvement and product launches on a world scale. Tevogen executives consider that accessible customized therapies are the following frontier in drugs and that disruptive enterprise fashions are wanted to help medical innovation.
Contacts
Tevogen BioCommunications
T: 1 877 TEVOGEN, ext. 701
Communications@Tevogen.com
Supply: Tevogen Bio Inc.
#Balancing #Entry #Outcomes #forty third #Annual #Morgan #Healthcare #Convention #Investing.com , #Gossip247
,
